Asset profile
ALTO-300
Small molecule
Evidence outlook · lead readout
NCT05118750 · Major Depressive Disorder
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT05118750: The study enrolled 91 participants in a single-group, open-label design with no placebo or active comparator, and assessed clinical depression scales including MADRS and CGI-S. No primary-endpoint results have been posted, so the treatment effect cannot be compared with a control group or determined from the registry.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.